The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis

Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy with a variable clinical outcome. Biomarkers of CLL progression are required for optimising prognosis and therapy. The Inhibitor of Bruton’s tyrosine kinase—isoform α (IBTKα) gene encodes a substrate receptor of Cullin 3-depend...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cell Death Dis
Main Authors: Albano, Francesco, Chiurazzi, Federico, Mimmi, Selena, Vecchio, Eleonora, Pastore, Arianna, Cimmino, Clementina, Frieri, Camilla, Iaccino, Enrico, Pisano, Antonio, Golino, Gaetanina, Fiume, Giuseppe, Mallardo, Massimo, Scala, Giuseppe, Quinto, Ileana
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5849039/
https://ncbi.nlm.nih.gov/pubmed/29317636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0026-3
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares